Meyka Pro banner
Stablecoin Development Corp.

Stablecoin Development Corp. (AMEX: SDEV) Stock Competitors & Peer Comparison

See SDEV's competitors and their performance on the AMEX and across the wider stock market.

SDEVAMEX
HealthcareMedical - Pharmaceuticals
$1.02
$0.01(0.97%)
U.S. Market opens in 12h 39m

Peer Comparison Table: Medical - Pharmaceuticals Industry

Detailed financial metrics including price, market cap, P/E ratio, and more for SDEV and its AMEX peers.

SymbolPriceChange %Market CapP/E RatioEPSDividend Yield
SDEV$1.02-0.97%27.6M-0.18-$5.73+390.24%
RPRX$57.97+2.11%25.7B11.04$5.25+1.58%
CORT$114.23+3.12%12.3B326.37$0.35N/A
WBA$11.98+0.50%10.4B-1.64-$7.29+4.17%
LQDA$91.03+0.90%8.1B650.21$0.14N/A
KNSA$76.53+0.62%5.8B85.03$0.90N/A
TRLV$9.08+3.77%1.5B-21.50-$0.42N/A
HROWL$25.61+0.19%1.4BN/AN/AN/A
HROWM$26.03-0.08%1.3BN/AN/AN/A
LTGO$18.56+1.70%1.1BN/AN/AN/A
1

Stock Comparison

Select a stock to compare (requires JavaScript). Showing default comparison.

Royalty Pharma plc (NASDAQ: RPRX)

SDEV vs RPRX Comparison August 2026

Stablecoin Development Corp. (AMEX: SDEV) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SDEV stands at 27.6M. In comparison, RPRX has a market cap of 25.7B. Regarding current trading prices, SDEV is priced at $1.02 on the AMEX, while RPRX trades at $57.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SDEV currently has a P/E ratio of -0.18, whereas RPRX's P/E ratio is 11.04. In terms of profitability, SDEV's ROE is +7.90%, compared to RPRX's ROE of +0.12%. Regarding short-term risk, SDEV is more volatile compared to RPRX. This indicates higher risk in terms of short-term price fluctuations for SDEV.Check RPRX's competition here

Stock price comparison of stocks in the Healthcare Sector

Loading...

Frequently Asked Questions